NovoMic

Company Overview

Snapshot

Founded in July 2014, NovoMic operated with 1–10 employees, focusing on health tech solutions. The company was acquired by TRAISTMAN RADZIEJEWSKI FUNDACJA in January 2020, marking a significant exit in its operational history.

Business overview

NovoMic specializes in developing and producing Novokid, a 100% natural dry treatment for lice and nits. The company's patented technology utilizes vaporized plant-based ingredients, offering a chemical, pesticide, and silicon-free solution. Operating within the Health Tech & Life Sciences sector, specifically Medical Treatment & Therapeutics, NovoMic serves the global market with a focus on children's hygiene and medical products.

Strategic signal

In January 2020, NovoMic was acquired by TRAISTMAN RADZIEJEWSKI FUNDACJA. This acquisition signifies the culmination of NovoMic's journey as an independent entity, integrating its innovative dry lice treatment technology into a larger corporate structure. For investors, this event demonstrates a successful exit strategy and the market's validation of NovoMic's product and intellectual property.

Company Intelligence Q&A

What was a significant corporate event for NovoMic in January 2020?

In January 2020, NovoMic was acquired by TRAISTMAN RADZIEJEWSKI FUNDACJA. This transaction involved TRAISTMAN RADZIEJEWSKI FUNDACJA acquiring 90% of NovoMic's issued and outstanding capital stock from TechCare.

What was NovoMic's relationship with TechCare prior to the acquisition?

NovoMic merged with BreedIT in October 2016 to form TechCare and subsequently operated as a wholly owned subsidiary of TechCare until its acquisition in January 2020.

What strategic partnership did TechCare, NovoMic's parent company at the time, enter into in January 2019?

In January 2019, TechCare entered into a joint venture contract with China-Israel Biological Technology Co. Ltd. (CIB) to develop products for the Asian market, as reported by Calcalistech.

Who was appointed as the Chief Executive Officer of NovoMic in January 2019?

In January 2019, TechCare appointed Osnat Philipp, a former executive from Lumenis, P&G, and Teva Pharmaceuticals, as the Chief Executive Officer of NovoMic.

What type of product does NovoMic develop?

NovoMic develops Novokid, a 100% natural dry treatment for lice and nits, utilizing patented technology that vaporizes plant-based ingredients.